Quttainah Hospital strengthens its aesthetic leadership with the official UAE launch of Avéli®

UAE—Quttainah Specialized Hospital Dubai has officially launched Avéli®, marking its introduction to the United Arab Emirates and further strengthening the hospital’s position as a regional leader and training center for advanced aesthetic medicine.

The launch follows the hospital’s recent renewal of its Joint Commission International (JCI) accreditation, reaffirming its dedication to patient safety, ethical practices, and high-quality elective healthcare services.

Avéli® stands out as the first and only U.S. FDA-cleared device designed to identify and precisely release the fibrous septae responsible for cellulite dimpling.

This innovation represents a new era in evidence-based aesthetic treatments and reflects the region’s increasing demand for advanced, technology-driven solutions in cosmetic care.

The event gathered leading specialists and practitioners from across the UAE and beyond to gain firsthand insights into the technology’s clinical applications.

The launch was led by Dr. Alfredo Hoyos, a globally renowned plastic surgeon and the pioneer behind the high-definition liposuction technique.

Widely regarded as one of the most influential voices in aesthetic body contouring, Dr. Hoyos also serves as the global opinion leader and ambassador for Avéli®, reflecting his central role in evaluating and validating innovative medical technologies.

A key highlight of the event was a live surgical demonstration conducted by Dr. Hoyos, offering attending physicians an in-depth look at the technique’s precision, safety, and efficacy.

The demonstration reinforced the importance of structured medical training and expert-led education in integrating new technologies responsibly into clinical practice.

It also provided participants an opportunity to observe how Avéli® works to address cellulite at its structural source rather than treating only its surface appearance.

Avéli® is a minimally invasive, single-session, in-office procedure that allows physicians to target and release the fibrous bands beneath the skin that cause dimpling and uneven texture.

Supported by clinical evidence, the procedure delivers visible and long-lasting improvement, with results that can be sustained for one year or more.

Its adoption in the UAE reflects growing interest in precision-based, scientifically validated approaches to aesthetic enhancement.

Speaking at the event, Dr. Hoyos emphasized that his role as a global opinion leader is to assess whether a technology delivers consistent, reproducible results in real-world medical settings.

He described Avéli® as a major step forward in cellulite treatment, noting that live demonstrations ensure the technology is applied safely and aligned with international best practices.

Dr. Adel Quttainah, CEO and Founder of Quttainah Specialized Hospital Dubai, highlighted that hosting the official UAE launch under Dr. Hoyos’s leadership exemplifies the hospital’s dedication to innovation, education, and clinical excellence.

He added that the hospital serves both as a treatment destination and as a reference center for introducing globally approved medical advancements responsibly and professionally.

The launch of Avéli® further reinforces Quttainah Specialized Hospital’s reputation as a trusted hub for advanced aesthetic care, professional training, and medical innovation—supported by a team of expert specialists and cutting-edge facilities designed to meet international standards.